Molecular Targeted Therapy of Lung Cancer
This book discusses the latest molecular targeted therapy of lung cancer including its evaluation and future directions. It clearly illustrates the initial dramatic effectiveness of molecular targeted therapy, recurrence of the disease, overcoming the wid
- PDF / 9,803,755 Bytes
- 321 Pages / 439.42 x 683.15 pts Page_size
- 11 Downloads / 228 Views
Yuichi Takiguchi Editor
123
Molecular Targeted Therapy of Lung Cancer
Yuichi Takiguchi Editor
Molecular Targeted Therapy of Lung Cancer
Editor Yuichi Takiguchi Department of Medical Oncology Graduate School of Medicine Chiba University Chiba, Japan
ISBN 978-981-10-2000-1 ISBN 978-981-10-2002-5 (eBook) DOI 10.1007/978-981-10-2002-5 Library of Congress Control Number: 2017930607 © Springer Science+Business Media Singapore 2017 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer Nature Singapore Pte Ltd. The registered company address is: 152 Beach Road, #22-06/08 Gateway East, Singapore 189721, Singapore
Preface
In 2004, a randomized study involving patients with advanced non-small cell lung cancer (NSCLC) demonstrated a 1.7 months’ benefit in median overall survival time (OS) with the combination chemotherapy consisting of docetaxel and cisplatin (median OS of 11.3 months) over the combination chemotherapy consisting of vindesine and cisplatin (median OS of 9.6 months) [1]. Although this study changed the 20-year standing standard of care for patients with advanced NSCLC that was established at 1981 [2], the survival time advantage was very small. From that time up to now, however, by adding an antiangiogenesis agent to the standard combination chemotherapy [3], by including newer agents [4, 5], and by incorporating maintenance therapy [6], a small advantage in each landmark study had steadily accumulated up to 16.9 months of median OS [6], which was almost twice long compared to the one with vindesine plus cisplatin. Although limited to patients with cancer harboring particular driver mutations, drastic prolongation of median OS has been observed by incorporating molecular-target agents [7–9]. Further improvement in prolonging OS is expected by incorporating newly developed immune checkpoint therapy [10, 11]. The advancement in the treatment for ad
Data Loading...
